Mitsune Ayumi, Yanagisawa Satoru, Fukuhara Tatsuro, Miyauchi Eisaku, Morita Mami, Ono Manabu, Tojo Yutaka, Ichinose Masakazu
Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Japan.
Department of Respiratory Medicine, Miyagi Cancer Center, Japan.
Intern Med. 2018 Jul 1;57(13):1893-1897. doi: 10.2169/internalmedicine.9153-17. Epub 2018 Feb 9.
Nivolumab is a newly introduced promising therapy for treating lung cancer that restores the anti-tumor immunity by disrupting programmed cell death-1-mediated immuno-suppressive signaling. Although "new-onset" autoimmune diseases are well-known immune-related adverse events, whether or not nivolumab exacerbates "pre-existing" autoimmune disease remains unclear. We herein report a patient with "pre-existing" myasthenia gravis in whom nivolumab was administered that flared up after the treatment with nivolumab. Regardless of the disease stability, nivolumab has the potential to exacerbate an autoimmune disease, and we must pay close attention to each patient's medical history before administering this agent.
纳武单抗是一种新推出的有前景的肺癌治疗药物，它通过破坏程序性细胞死亡-1介导的免疫抑制信号来恢复抗肿瘤免疫力。虽然“新发”自身免疫性疾病是众所周知的免疫相关不良事件，但纳武单抗是否会加重“已有的”自身免疫性疾病仍不清楚。我们在此报告一名患有“已有”重症肌无力的患者，在接受纳武单抗治疗后病情加重。无论疾病是否稳定，纳武单抗都有加重自身免疫性疾病的可能性，在使用该药物之前，我们必须密切关注每位患者的病史。
